drugset / Trial / NCT07593092
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
The primary purpose of this study is to determine whether the investigational drug XmAb541 in combination with XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 in combination with XmAb808 on tumor outcomes.
Timeline
- Start
- 2026-06
- Primary completion
- 2028-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XmAb541 | Monoclonal antibody | — | — |
| Subject | XmAb808 | Monoclonal antibody | — | — |